Renee D. Gala

Renee D. Gala appears in 58 filings published from February 23, 2016 to October 7, 2026, at four issuers: Jazz Pharmaceuticals plc (32, under the title President & COO), Theravance Biopharma, Inc. (20, under the title SVP, Chief Financial Officer), Dexcom Inc (4) and Corcept Therapeutics Inc (2), the last two as Director.

The 8 sales total EUR 3,208,090, with a median of EUR 407,271. The largest, EUR 938,004, is dated August 15, 2018 at Theravance Biopharma, Inc. Two sales at Jazz Pharmaceuticals plc follow: EUR 733,592 on May 18, 2023 and EUR 421,028 on October 6, 2026. The 2 purchases, at Corcept Therapeutics Inc, took place on March 6, 2018 and March 7, 2018: EUR 12,402, then EUR 112,567. The rest is 46 grants and 2 filings of another kind.

The year 2018 is the busiest, with 12 filings, and the record has only one filing in 2020. Nine filings fall in the last twelve months, 2 of them sales.

At Theravance Biopharma, Inc., Bradford J. Shafer has 4 trades close to those of Gala. Bruce C. Cozadd and Neena M. Patil have 3 at Jazz Pharmaceuticals plc, as does Philip D. Worboys at Theravance Biopharma, Inc., always in the same direction.